Home
Resources
Follow portfolio news
...

Healthcare: Biotheus operates in a market for antibody-drug conjugates that now exceeds $10 billion

Published on
31/7/2024
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
Biotheus
For the first time, the size of the global antibody-drug conjugate (ADC) market exceeded $10 billion last year, reaching an estimated $11.29 billion, according to Grand View Research. This trend is set to continue in the years ahead, with an estimated value of nearly $30 billion by 2028, according to market intelligence firm Evaluate.
By
Lou Freychet-Escudier
Lou Freychet-Escudier
Healthcare: Biotheus operates in a market for antibody-drug conjugates that now exceeds $10 billion
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

Antibody-drug conjugates, or ADCs, are a class of biopharmaceutical drugs designed as targeted therapies for the treatment of cancer.

Neha Rathod Godbole, Senior Analyst at Vantage Market Research, explains that "the CDA market is growing rapidly, driven by the rising incidence of cancer worldwide and the increasing demand for targeted therapies offering greater efficacy and fewer side effects compared to traditional treatments.". "Recent approvals of ADCs, such as Enhertu for breast cancer, underline their potential to transform treatment landscapes in oncology."

She notes that the ADC sector is also seeing an increase in investment and strategic collaborations. "Big Pharma is increasingly partnering with biotech companies to leverage cutting-edge technologies and accelerate the development of next-generation ADCs." "These alliances promote not only innovation, but also the scalability and commercial viability of ADC products."

This is particularly true of Biotheus, a clinical-stage company focused on the development of therapies for oncology and inflammatory diseases and present in the Vintage Altaroc Odyssey 2021, which announced a few months ago the expansion of its partnership with Hansoh Pharmaceutical Group.

The collaboration between the two China-based companies involves upfront and potential payments of RMB 5 billion ($694.8 million) to Biotheus. Biotheus will grant Hansoh a license to use its Phase I antibody PM1080/HS-20117 to develop ADC therapies.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Rest of the world
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.